Retatrutide weight loss injection: what the trial evidence actually shows

What the phase 2 trial data showed, and what it did not prove

The most-cited evidence for retatrutide comes from a phase 2 randomised controlled trial, results published in the New England Journal of Medicine in 2023. The trial enrolled 338 adults with obesity (BMI 30–50) who did not have type 2 diabetes. Over 48 weeks, participants receiving the highest dose studied (12 mg weekly) lost an average of around 17.5% of their body weight; a subgroup on an alternative titration schedule reached approximately 24%. Those figures circulated widely.

Phase 2 trials are designed to test safety, tolerability and dose-ranging in a relatively small number of people. They generate signals, not conclusions. The 338 participants enrolled here represent a fraction of the scale needed before regulators consider an application. Side effects in the trial were largely gastrointestinal (nausea, vomiting, diarrhoea and constipation were the most common) following a pattern familiar from other GLP-1 class medicines. Rates were broadly consistent with what phase 2 programmes for licensed medicines showed before those medicines reached larger studies. Phase 3 trials were initiated, but results and regulatory submissions had not been announced by mid-2026.

What the data did not address: long-term cardiovascular outcomes, durability of weight loss after stopping, safety in people with significant comorbidities at scale, or any of the other endpoints regulators require before granting a marketing authorisation. Phase 2 optimism has not always translated into phase 3 success in this therapeutic area. The science here is genuinely interesting; the medicine is not yet real, in any regulatory sense.

Retatrutide's mechanism, why the triple agonist approach attracted interest

Retatrutide works on three receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon. This sets it apart from currently licensed UK options. Tirzepatide, for example, activates the GIP and GLP-1 receptors, making it a dual agonist. Semaglutide activates GLP-1 alone. Adding glucagon receptor activity is the distinguishing feature of retatrutide's design.

Glucagon receptor agonism is thought to increase energy expenditure and promote fat breakdown through effects in the liver and adipose tissue, which may explain why the weight reductions seen in early trials appear larger than those reported at comparable stages for the dual-agonist and single-agonist predecessors. That mechanistic logic is plausible and the subject of active research. It also brings uncertainty: the glucagon pathway influences glucose regulation in ways that require careful management, and the long-term metabolic consequences of sustained triple receptor activation have not been characterised in large populations. If you are curious about how peptide injections for weight loss work more broadly, that context helps clarify where retatrutide sits in the landscape.

Eli Lilly is the developer, the same company that brought tirzepatide to market. That lineage contributes to the scientific credibility of the programme, though it does not accelerate the regulatory timeline.

What weight loss injection retatrutide side effects looked like in the trial

Data on weight loss injection retatrutide side effects comes exclusively from the phase 2 study and any interim phase 3 disclosures; there is no post-market safety database because the medicine has never been on the market. In the published phase 2 trial, nausea was the most frequently reported adverse event, affecting a substantial proportion of participants in the higher-dose groups. Vomiting, diarrhoea and constipation were also common. Most events were rated mild to moderate and occurred most often after starting treatment or after a dose increase, which again mirrors the established GLP-1 class profile.

The MHRA has not issued any guidance specific to retatrutide, because there is nothing for it to regulate yet. The Yellow Card scheme (where patients and clinicians report suspected side effects of licensed medicines) does not cover investigational drugs outside approved trials. Anyone encountering a seller claiming to offer retatrutide in the UK should treat that as a serious red flag: the medicine holds no UK authorisation, and any product marketed under that name domestically would not be what it claims to be. If you want to understand which weight loss injection criteria you might meet today, the answer involves licensed options, not unlicensed compounds.

Cost context is straightforward for retatrutide: there is no price to discuss, because there is no legal product. People researching costs alongside a new weight loss injection retatrutide hope are best served by looking at what licensed treatment actually involves, a subject covered on our weight management treatment overview.

Licensed options available in the UK now, and where retatrutide might fit later

For adults in the UK who meet clinical criteria today, two injectable weight-loss medicines hold NICE recommendations and MHRA authorisations. Tirzepatide (Mounjaro) is recommended by NICE under TA1026 for adults with a BMI of 35 or above alongside at least one weight-related condition, and is also licensed for type 2 diabetes management. Semaglutide (Wegovy) carries a NICE recommendation under TA875, with its own eligibility criteria and a 2-year NHS treatment limit when accessed through specialist services. Both are available privately through regulated pharmacies after a clinical assessment by a prescriber, with no waiting list for those who qualify.

SURMOUNT-1, the pivotal tirzepatide trial, reported average weight reductions of around 20–21% at the highest dose over 72 weeks in people without diabetes, figures that already match or exceed retatrutide's phase 2 headline numbers, in a far larger and more extensively reviewed dataset. A head-to-head trial comparing tirzepatide with semaglutide 2.4 mg (SURMOUNT-5, published in the NEJM in 2025) confirmed tirzepatide produced greater average weight loss. The evidence base for these licensed medicines is deep. Retatrutide's is nascent.

If and when retatrutide completes phase 3 trials and a developer submits an application to the MHRA, a review process would follow before any UK prescribing could begin, and our weight loss injections reta page will be updated to reflect any material changes to its regulatory status as they happen. For now, the practical question for most people is not whether retatrutide will eventually arrive, but what is clinically available today. Exploring the range of weight loss injections that are currently licensed is the more useful starting point, and the route to getting a weight loss injection through a regulated pharmacy is well established. Our clinical team reviews every consultation personally, and they are the right people to help you work through which licensed option fits your circumstances.

Speak to our prescribers through a free consultation if you would like to understand what is currently available and whether it may be suitable for you.